SEPN.NASDAQSepterna, INC

Form 4: Septerna Inc. Insider Trades: SVP Drug Discovery Buys and Sells Stock

Sentiment:

Insider Transaction Report


Septerna, Inc. SVP of Drug Discovery, Daniel D. Long, engaged in a series of stock transactions, acquiring shares through an employee stock purchase plan and options, while also selling a portion of his holdings.

Summary

  • Daniel D. Long, SVP of Drug Discovery at Septerna, Inc., reported transactions involving the company's common stock on June 22, 2026.
  • Long acquired 10,529 shares at $2.76 each and 4,471 shares at $11.70 each, totaling 15,000 shares.
  • These acquisitions were made under the Septerna, Inc. 2024 Employee Stock Purchase Plan and through stock options.
  • Additionally, Long sold 8,000 shares at a weighted average price of $35.1001 and 7,000 shares at a weighted average price of $35.9687, totaling 15,000 shares.
  • These sales were executed as part of a Rule 10b5-1 sales plan adopted on March 20, 2026.
  • Following these transactions, Long beneficially owns 103,412 shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves significant stock transactions by a key executive, the sales are executed under a pre-arranged plan, and the acquisitions suggest continued employee participation. The net effect on sentiment is balanced between profit-taking and ongoing investment.

Positives

  • Daniel D. Long acquired 15,000 shares of Septerna, Inc. common stock, indicating continued investment in the company.
  • Acquisitions were made at lower price points ($2.76 and $11.70), potentially representing favorable entry points for the insider.
  • The acquisition of shares through the Employee Stock Purchase Plan suggests participation in a company-sponsored program designed to benefit employees.

Negatives

  • Daniel D. Long sold a total of 15,000 shares of Septerna, Inc. common stock.
  • The sales were executed at significantly higher prices ($35.1001 and $35.9687) compared to the acquisition prices, suggesting profit-taking by the insider.

Risks

  • The sales were conducted under a Rule 10b5-1 trading plan, which is designed to provide an affirmative defense against allegations of insider trading. However, the adoption of such a plan can sometimes be interpreted by the market as a signal of an insider's intention to sell shares regardless of future company performance.
  • The significant difference between the acquisition prices and the sale prices could indicate that the insider believes the stock may have reached a peak or is overvalued at current levels.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are closely watched by the market. While these plans are designed to facilitate orderly selling and avoid insider trading accusations, the timing and volume of such trades can still influence investor sentiment and stock price movements. The reported transactions by Septerna's SVP of Drug Discovery reflect a common pattern of employees acquiring stock at lower prices (often through grants or purchase plans) and selling at higher prices as part of a pre-determined strategy.

Stakeholder Impact

  • Shareholders: The sale of shares by a senior executive could be interpreted by some shareholders as a negative signal, potentially impacting short-term stock price. However, the sales were conducted under a Rule 10b5-1 plan, mitigating concerns of opportunistic insider trading.
  • Employees: The acquisition of shares through the Employee Stock Purchase Plan may encourage other employees to participate, fostering a sense of shared ownership and aligning employee interests with the company's performance.
  • Management: The transactions reflect the standard compensation and equity management practices for senior executives in the industry.

Key Dates

DateDescription
03/20/2026Date Rule 10b5-1 sales plan was adopted by the Reporting Person.
04/30/2026Date of acquisition of 3,501 shares under the Septerna, Inc. 2024 Employee Stock Purchase Plan.
06/22/2026Date of transactions reported in the filing, including acquisitions and dispositions of common stock.
06/24/2026Date the Form 4 was signed by the Reporting Person's Attorney-in-Fact.

Keywords

Form 4, Insider Trading, Septerna Inc., SEPN, Daniel D. Long, Stock Options, Employee Stock Purchase Plan, Rule 10b5-1, Beneficial Ownership, Stock Sales, Stock Acquisitions

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.